United States Biotechnology & Medical Research

Annovis Bio Inc (ANVS)

Track

Annovis Bio Inc. recorded three insider trading transactions over the past ninety days, all representing open market purchases totaling approximately $142,779. These acquisitions occurred following a recent earnings report that missed expectations. Despite a 21.3% decline in stock price during this period, buying activity remains concentrated among a single individual.
Ticker: ANVS Exchange: ASE
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Annovis Bio Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Buy 20 May 2026
Value US$3,439,954.33 | Price 187.27 | Shares 952 (+14.1%)
Buy 20 May 2026
Value US$3,136,470.12 | Price 210.86 | Shares 84,690 (+23.0%)
Buy 20 May 2026
Value US$4,483.50 | Price 1.75 | Shares 2,562 (+0.1%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-05-21 2026-05-20 B Purchase
3.6
Hoffman Michael B
Non-Executive Director
952 +14.1%
187.27
US$3,439,954 		952 +14.1% 187.27 US$3,439,954
2026-05-21 2026-05-20 B Purchase
3.6
Hoffman Michael B
Non-Executive Director
84,690 +23.0%
210.86
US$3,136,470 		84,690 +23.0% 210.86 US$3,136,470
2026-05-21 2026-05-20 B Purchase
3.6
Hoffman Michael B
Non-Executive Director
68,036 -1.9%
281.26
US$1,204,767 		68,036 -1.9% 281.26 US$1,204,767
2026-04-03 2026-04-02 B Purchase
3.6
Hoffman Michael B
Non-Executive Director
713,800 +27.7%
2.10
US$1,498,980 		713,800 +27.7% 2.10 US$1,498,980
2026-04-02 2026-04-02 PrS Proposed sale
1.9
White Mark K.

Director

Non-Executive Director
7,142
2.08
US$14,848 		7,142 2.08 US$14,848
2025-12-08 2025-12-08 B Purchase
3.6
Hoffman Michael B
Non-Executive Director
15,000 +0.6%
4.24
US$63,600 		15,000 +0.6% 4.24 US$63,600
2025-12-08 2025-12-08 B Purchase
3.6
Hoffman Michael B
Non-Executive Director
30,000 +1.2%
4.34
US$130,194 		30,000 +1.2% 4.34 US$130,194
2025-11-25 2025-11-24 B Purchase
3.6
Hoffman Michael B
Non-Executive Director
28,096 +1.1%
4.15
US$116,598 		28,096 +1.1% 4.15 US$116,598
2025-11-25 2025-11-24 B Purchase
3.6
Hoffman Michael B
Non-Executive Director
415 +0.0%
4.14
US$1,718 		415 +0.0% 4.14 US$1,718
2025-11-25 2025-11-24 B Purchase
3.6
Hoffman Michael B
Non-Executive Director
9,200 +0.4%
3.85
US$35,420 		9,200 +0.4% 3.85 US$35,420
2025-11-25 2025-11-24 B Purchase
3.6
Hoffman Michael B
Non-Executive Director
1,489 +0.1%
4.13
US$6,150 		1,489 +0.1% 4.13 US$6,150
2025-11-21 2025-11-21 B Purchase
3.6
Hoffman Michael B
Non-Executive Director
10,000 +0.4%
3.50
US$35,000 		10,000 +0.4% 3.50 US$35,000
2025-11-21 2025-11-21 B Purchase
3.6
Hoffman Michael B
Non-Executive Director
10,000 +0.4%
3.49
US$34,900 		10,000 +0.4% 3.49 US$34,900
2025-11-18 2025-11-14 B Purchase
3.6
Hoffman Michael B
Non-Executive Director
15,000 +0.6%
2.11
US$31,650 		15,000 +0.6% 2.11 US$31,650
2025-11-12 2025-10-28 B Purchase
3.6
Hoffman Michael B
Non-Executive Director
975,610 +65.9%
2.05
US$2,000,000 		975,610 +65.9% 2.05 US$2,000,000
2025-11-12 2025-10-28 B Purchase
2.6
Maccecchini Maria-Luisa

President & CEO

Executive Director
97,561 +8.8%
2.05
US$200,000 		97,561 +8.8% 2.05 US$200,000
2021-10-13 2021-10-12 B Purchase
1.9
White Mark K.
Non-Executive Director
5,000 +9.8%
27.40
US$137,000 		5,000 +9.8% 27.40 US$137,000
2021-10-13 2021-10-11 B Purchase
1.4
Bruck Claudine
Non-Executive Director
181 +3.1%
27.66
US$5,006 		181 +3.1% 27.66 US$5,006
2021-10-13 2021-10-11 B Purchase
2.6
Maccecchini Maria-Luisa

PRESIDENT AND CEO

Executive Director Large shareholder
18,000 +1.9%
27.61
US$496,980 		18,000 +1.9% 27.61 US$496,980
2020-02-05 2020-02-03 B Purchase
0.8
McGroarty Jeffrey Brian

Chief Financial Officer
164 +0.3%
7.17
US$1,176 		164 +0.3% 7.17 US$1,176
2020-02-05 2020-02-03 B Purchase
0.8
McGroarty Jeffrey Brian

Chief Financial Officer
19,336 +58.0%
7.15
US$138,252 		19,336 +58.0% 7.15 US$138,252
2020-02-05 2020-01-31 B Purchase
2.5
Whelan, Jr. Robert M.
25,000 +inf%
6.00
US$150,000 		25,000 +inf% 6.00 US$150,000
2020-02-05 2020-01-31 B Purchase
1.9
White Mark K.
1,734 +inf%
6.00
US$10,404 		1,734 +inf% 6.00 US$10,404
2020-02-05 2020-01-31 B Purchase
0.8
McGroarty Jeffrey Brian

Chief Financial Officer
33,333 +inf%
6.00
US$199,998 		33,333 +inf% 6.00 US$199,998
2020-02-05 2020-01-31 B Purchase
3.6
Hoffman Michael B
Large shareholder
33,333 +233.3%
6.00
US$199,998 		33,333 +233.3% 6.00 US$199,998
2020-02-05 2020-01-31 B Purchase
2.6
Maccecchini Maria-Luisa

President and CEO

Executive Director Large shareholder
1,600 +0.8%
6.00
US$9,600 		1,600 +0.8% 6.00 US$9,600
2020-02-05 2020-01-31 B Purchase
1.4
Bruck Claudine
800 +inf%
6.00
US$4,800 		800 +inf% 6.00 US$4,800
Explore more

More insider trading research around Annovis Bio Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America